LPI-labile plasma iron in iron overload
|
|
- Clare McDonald
- 6 years ago
- Views:
Transcription
1 Best Practice & Research Clinical Haematology Vol. 18, No. 2, pp , 2005 doi: /j.beha available online at 9 LPI-labile plasma iron in iron overload Z. Ioav Cabantchik* MD, PhD Professor of Biochemistry and Head of Life Sciences Program William Breuer PhD Research Associate Department of Biological Chemistry, Institute of Life Sciences, Hebrew University of Jerusalem, Jerusalem, Israel G. Zanninelli MD Attending Physician P. Cianciulli MD Director Unita Day Hospital Talassemici, Ospedale Sant Eugenio, Rome, Italy Labile plasma iron (LPI) represents a component of non-transferrin-bound iron (NTBI) that is both redox-active and chelatable, capable of permeating into organs and inducing tissue iron overload. It appears in various types of hemosiderosis (transfusional and non-transfusional) and in other iron-overload conditions. Sustained levels of LPI could over time compromise organ (e.g. heart) function and patient survival. With the advent of methods for measuring LPI in the clinical setting, it has become possible to assess the implications of LPI in the management of iron overload based on regimens of iron chelation. As LPI is detected primarily in patients with transfusional iron overload and other forms of hemosiderosis, we review here regimens of iron chelation with deferrioxamine and deferiprone (separately or combined) in terms of their efficacy in minimizing daily exposure to LPI in thalassemia major and thalassemia intermedia patients. Key words: labile plasma iron; iron overload; thalassemia; hemosiderosis; transfusion; hemochromatosis; ascorbate; oxidative stress; fluorescence; high throughput assay. Chronic diseases of iron overload have two distinct features: (1) plasma iron levels become excessively high, and (2) sustained excess of plasma iron leads to iron accumulation in the liver, endocrine organs and heart. Excessive iron accumulation in the respective organ is the cause of liver fibrosis and ensuing hepatic dysfunctions (including hepatocarcinomas), diabetes and cardiomyopathies. 1,2 * Corresponding author. Tel.: C ; Fax: C address: ioav@cc.huji.ac.il (Z.I. Cabantchik) /$ - see front matter Q 2004 Elsevier Ltd. All rights reserved.
2 278 Z. I. Cabantchik et al. The major therapeutic approaches in the treatment of transfusional iron overload or hemosiderosis are based on iron chelators that are assessed in terms of their capacity to reduce body iron burden, primarily by complexing and eliminating liver iron. 2 4 The clinical efficacy of chelation therapy has been generally evaluated by following up classical parameters such as plasma ferritin (often, but not uniquely, a measure of iron stores) and serum iron (usually in conjunction with total iron binding capacity and/or transferrin saturation). 2,5 More specific measures of iron overload of clinical relevance have relied on the biochemical and histochemical analysis of biopsies taken from particular organs, usually the liver. 6 Magnetic susceptometry (SQUID) 5 9 and recently also magnetic resonance imaging (MRI) have offered the possibility of in situ assessment of iron accumulation in liver or heart by non-invasive means. However, hitherto little attention has been given to the nature and source of iron that circulates in the plasma and interstitial fluids and is assumed to be the primary vehicle of tissue iron overload and ensuing toxicity. That source of iron is not identified either with transferrin (which is highly iron-saturated in virtually all the ironoverloaded patients in question) or with ferritin, whose plasma levels generally reflect iron stores but also rise in conditions unrelated to iron overload per se (e.g. chronic inflammation). The circulating forms of iron that lead to tissue iron overload and are not tightly associated with plasma transferrin have been generically termed non-transferrinbound iron (NTBI). 17 In general, NTBI emerges whenever the capacity of transferrin to incorporate incoming iron (from the gut or reticuloendothelial cells) becomes a limiting factor, either because of insufficient binding capacity per se or for kinetic reasons. Although NTBI and labile plasma iron (LPI) appear primarily in highly transfused patients whose transferrin iron-binding capacity has been surpassed 18 20, they are often found at transferrin saturations well below 100% Failure of iron to be incorporated into transferrin results in its association with other plasma components. The chemical structures comprising NTBI might vary with the degree of iron overload, encompassing forms that are readily chelated by commonly used chelating agents as well as others that can be chelated only if they are first extracted from their adsorption sites with high concentrations of mobilizing agents. 18 However, the pathologically relevant fraction of NTBI is that which is seemingly translocated across cell membranes in a non-regulated manner and leads to excessive iron accumulation in liver, heart, pancreas and other endocrine organs. 22,23 That fraction is referred to as labile plasma iron (LPI) since it encompasses cell-penetrating forms of iron that are redox active and susceptible to chelation. These attributes render LPI not merely an accessible diagnostic marker of iron overload and cell toxicity but also a clinical parameter that could be used for assessing the mode and efficacy of iron chelation. The design of iron chelators has classically focused on agents aimed at reducing the body iron burden by acting on the major sites of iron accumulation and thus indirectly reducing the levels of the metal in plasma and interstitial fluid. Agents conforming to that design are desferrioxamine (DFO) and ICL670, both of which act directly on liver iron and excrete it via the biliary route, and deferiprone (used either alone or in combination with DFO), which also seemingly extracts iron from liver, but carries it into plasma for secretion via the urinary tract. 3,4,24 However, the other mode by which chelators such as DFO and deferiprone might reduce LPI is by direct capture of LPI itself, thus preventing iron entry into organs (such as the heart) of iron-overloaded patients. For such a strategy there might be a need for maintaining constant basal levels
3 LPI-labile plasma iron in iron overload 279 of plasma chelating activity during most hours of the day. A third mode of chelator action relies on the ability of the chelator to permeate extrahepatic tissue such as heart or pancreas and thereby neutralize the cytotoxic activity associated with accumulated iron. Deferiprone and ICL670 apparently fit that category, although the capacity of the chelates to exit cells probably varies considerably between the two agents. Optimal results are expected to be obtained with agents or regimens that display the three modes of chelation, whether based on these same drugs or their combination. WHY ANOTHER ASSAY FOR ASSESSING IRON OVERLOAD? Despite the success of daily DFO treatment in maintaining thalassemia major patients in negative iron balance over more than three decades, a significant number of patients have apparently developed serious and often fatal heart conditions. 25,26 In many cases these conditions could be attributed to iron accumulation in the heart rather than the liverdue to their low correlations with liver iron or circulating ferritin. 9 16,27 29 The proposed view is that the treatment (in most cases night-time infusion of DFO) might not have precluded repetitive exposure of the heart to circulating forms of labile iron that could lead to critical accumulation of the metal in cardiomyocytes via the divalent metal transporter DMT1 30 and/or dihydropyridine-sensitive L-type calcium channels. 31 Since this phenomenon seems to be less prevalent or non-existent in patients treated with DFO continuously (24 hours) 32, and since therapeutic plasma levels of DFO apparently do not affect transferrin-bound iron 2, it is reasonableto assume that anychelation treatment that could attenuate formation of LPI would minimize or prevent the deleterious effects of iron on extrahepatic tissue. This raises the outstanding questions of whether LPI monitoring could be used for assessing the efficacy of iron chelation treatment, and whether any clinical endpoints correlate with measurable LPI levels. As stated above, LPI refers to that component of plasma NTBI that is redox active, chelatable, and capable of entering (substantially) into cells. This LPI component of NTBI appears primarily in patients with hemosiderosis whose transferrin saturation levels exceed 80G5%, irrespective of the etiological reason. 22,23,33 Recent epidemiological studies indicated that cardiac complications related to iron overload are most prevalent in patients with a transferrin saturation higher than 85%. 11 Such correlations provide the basis for the link between cardiac complications in iron overload and LPI. What they imply for the medical practitioner is that assessment of iron chelation regimens based solely on serum ferritin levels or other classical parameters of liver iron provide only a fragmentary and often misleading picture of the iron status of patients and the quality of treatment. Therefore, despite an apparently adequate liver iron extraction quotient, a daily chelation treatment might still leave wide windows of exposure to LPI that over time could compromise the patient s health. Can measurements of LPI provide a direct index for the efficacy of a chelation treatment of iron-overloaded patients, and if so, can LPI levels be correlated with the risk of iron accumulation in the heart? LPI LEVELS IN THALASSEMIA A new high-throughput technology (FeROS, Aferrix Ltd) was recently devised for assessing LPI in the clinical setting and has already been applied to more than 5000 serum samples, including patients with thalassemia (major and intermedia) 22,23,34,
4 280 Z. I. Cabantchik et al. hemochromatosis 22,33, diabetes 35, dysmetabolic hepatosiderosis 33, and myelodysplasmic syndrome. 36 The assay is based on the capacity of LPI to generate reactive oxygen radicals when prompted with ascorbate in a manner blockable by specific iron chelators. 22 LPI was detected in more than 75% of randomly selected b- thalassemia patients undergoing regular blood transfusions and chelation treatment and non-transfused hemoglobin E (HbE)/b-thalassemia patients. The LPI levels vary from 0.4 to 10 mm, depending on the nature of the disease, the transfusion schedule, the chelation regimen, and the time of blood sampling relative to the drug administration. The following sections provide three examples of LPI measurements in clinical studies aimed at evaluating different regimens of chelation in iron-overloaded patients. Example 1: LPI in HbE/(-thalassemia patients during an 80-week course of deferiprone treatment (modified from reference 23) A group of 17 Thai patients (non-transfused and non-chelated for more than 1 year) were subjected prospectively to a course of long-term deferiprone treatment (50 mg/kg/d in two doses, morning and evening) (Figure 1). Bimonthly values of LPI, serum ferritin and red-cell-membrane-associated iron for the entire cohort are depicted as stacked areas. The height of the stack represents the mean value at the indicated time point. Daily administration of deferiprone for months caused LPI 3.0 Thalassemia intermedia 2.5 LPI, SF or RBCM-I (r.u.) L1-months of treatment LPI SF RBCM-I Figure 1. The figure depicts the mean basal LPI, serum ferritin (SF) and red-blood-cell-membrane-associated iron (RBCM-I) value s relative to those obtained on entry into the study in 17 HbE/b-thalassemia patients treated with deferiprone orally (50 mg/kg/d in two doses) for up to 18 months; blood samples were withdrawn every 2 months in the morning after at least 10 hour washout of deferiprone. The height of a given area at a particular month depicts the level of the parameter relative to that at the onset of the treatment. The actual mean values of each parameter at the beginning of treatment (month 1) were: for LPI 4.7G0.5 mm; for RBCM iron 8.0G1.5 nmol/mg protein, and for SF 3407G868 ng/ml. Data modified from Pootrakul P et al (2004, Blood in press) with permission.
5 LPI-labile plasma iron in iron overload 281 to decrease from an initial corrected mean level of 4.7G0.5 mm (measured before the morning intake of deferiprone) to steady mean levels of 1.8G0.2 mm, attaining steady lowest levels after 6 8 months with a t 1/2 of 2 3 months. Serum ferritin and red-cell-membrane-associated iron followed a similar course, but attained steady basal levels only after months of continuous treatment with a t 1/2 of 5 7 months. On the other hand the percentage transferrin saturation and total serum iron remained elevated throughout the entire course of treatment. This study indicated that persistent levels of LPI values detected during daily drug washout periods can serve as early indicators of iron overload and as a measure of the effectiveness of iron chelation in reducing potentially toxic iron in the plasma of thalassemia intermedia patients. Moreover, the study also showed that the particular regimen of deferiprone applied for more than a year to the indicated set of patients was not sufficient to bring down LPI basal levels to the threshold level of 0.6 mm which represented the 0.4 mmg0.2 SD detection sensitivity level of the assay. A possible explanation is that, for the group of patients in question, the rate of LPI removal by a 50 mg/kg/d dose of deferiprone was in steady state with the rate of iron replenishment. Further reduction in LPI might demand an intensified treatment based on higher deferiprone dosage, possibly more spread out during the day. However, it should be stressed that the clinically relevant threshold levels of LPI, whether assessed as basal levels or in terms of cumulative daily exposure to LPI, still need to be more strictly defined in carefully planned longitudinal studies. Example 2: daily LPI levels in b-thalassemia patients undergoing different iron chelation treatments A group of 30 thalassemia major patients, who had been treated for years with DFO only (40 mg/kg/d subcutaneously), were subdivided into three treatment groups (nz10 each): one continued with DFO overnight, one switched to daily deferiprone taken orally (75 mg/kg/d in three doses), and one switched to a combination of daily deferiprone and overnight DFO (Figure 2). Patients were chosen for treatment with deferiprone because of compliance problems with DFO, and for treatment with DFO plus deferiprone because of persistently high serum ferritin levels despite the previous DFO treatment. The individual daily profiles of LPI for each group obtained after more than 12 months of treatment are shown in Figure 2 (samples were taken every 2 hours during the day, from 8 a.m. until midnight, and next day at 8 a.m. indicated as 32 hours, and where applicable before drug intake). The individual profiles are stacked one above the other, and the height of each stack represents the actual LPI value at the indicated hour of treatment. For DFO-treated patients LPI was essentially undetectable during the course of DFO infusion (Figure 2, top), while it gradually rose afterwards, peaking at evening hours just before the next infusion. In seven out of ten patients the LPI levels did not rise above 0.6 mm during the day, in two they rose moderately during the late afternoon and early evening hours, and in one they rose considerably within 2 hours after treatment and thereafter throughout the day until the next infusion. For deferiprone-treated patients (Figure 2, middle) The mean basal LPI levels (detected after a 10-hour washout period, namely, after the last deferiprone dose) were in the range mm on two consecutive days. The basal
6 282 Z. I. Cabantchik et al Thalasemia major mg/kg/day DFO LPI µm LPI µm hr sampling/treatment Thalasemia major L1 75 mg/kg/day hr treatment Figure 2. Daily LPI levels in individual thalassemia major patients treated with different chelators. The following depict the individual LPI values obtained in groups of 10 thalassemia major patients (individually indicated by a different color) treated either with DFO subcutaneously at 40 mg/kg/d (top: blue box duration of infusion), deferiprone orally (75 mg/kg/d) (middle: separate doses indicated by arrows) or combined therapy (bottom: arrows for deferiprone and blue box for DFO infusion). Blood samples were taken at 2-hour intervals from 8 a.m. to midnight (the 32-hour point represents the sample 24 hours after the first sample was taken). The area under each line represents individual results stacked one above the other. The height of a given area at a particular time depicts the level of LPI at the indicated hour of sampling. The white mesh represents the 0.4 precision limit of the assay or background level found in sera from normal individuals. From Zanninelli et al (2004, Proceedings of the European Iron Club meeting, Rennes 2004) with permission.
7 LPI-labile plasma iron in iron overload Thalasemia major L1 75 mg/kg/day mg/kg/day DFO LPI µm hr sampling/treatment (hr) Figure 2 (continued) LPI values were found to be representative of the individual profiles. In five out of ten patients the basal LPI levels were significantly higher than the threshold value of 0.6 mm; LPI generally fell after deferiprone intake but gradually rose back during washout periods longer than 2 hours. In the remaining five patients LPI levels fluctuated (i.e. fell after drug intake and rose gradually during the washout period), but were maintained within the lower 0.6 mm range, indicating the adequacy of the standard deferiprone monotherapy for this subgroup of patients. For deferiprone-plus-dfo-treated patients (Figure 2, bottom) LPI levels did not exceed the 0.6 mm threshold level during the entire 24-hour follow up. In fact, in all cases except one the levels were maintained even below the 0.4 mm range. The implication of the above results is that the washout levels of LPI provide a good measure of the general efficacy of the chelation treatment. On the basis of the known pharmacokinetics of deferiprone and DFO, a chelator washout period of 4 hours was already sufficiently long to preclude interference with LPI determination. This entailed sampling at about 8 a.m. for deferiprone-treated patients (previous deferiprone taken the night before) and 8 10 p.m. for patients treated with DFO alone or in combination with deferiprone (previous deferiprone dose taken at midday and DFO infusion completed in the early morning). The mean basal (post-washout) LPI values correlated linearly (r 2 Z0.90) with the respective mean levels of serum ferritin attained with the different treatments. The analysis yielded a linear correlation with a slope of 0.40G 0.12 mm LPI per mg/ml ferritin (typical pairs of LPI in mm and ferritin G0.06 mg/ml) values were: 0.25G0.06 and 0.456G0.092 for deferiprone-plus-dfo; 0.69G0.22 mm and 1.881G0.665 for DFO alone, and 0.95G0.27 and 2.006G0.416 for deferiprone alone. Our experience with the relatively small cohort of patients engaged in the study (ten per group) indicates that the combination of deferiprone-plus-dfo provided not
8 284 Z. I. Cabantchik et al. only the lowest LPI values throughout the entire day, and the lowest serum ferritin values, but gave also the most uniform response to the chelation treatment. Example 3: LPI levels in b-thalassemia patients undergoing treatment with the daily dose of deferiprone divided into three versus four This study was aimed at assessing the possibility of diminishing the daily LPI levels by spreading out the oral deferiprone intake over the day (same final dose, but divided into four instead of three doses per day) (Figure 3). For that purpose, the same group of thalassemia major patients who were treated previously with 75 mg/kg/d deferiprone in three daily doses (Figure 2) were switched to four doses and their mean daily LPI levels compared (Figure 3). The mean basal levels of LPI (at 8 a.m. and, 24 hours later, at 32 hours) remained essentially the same for both treatments (1.15G0.20 mm; range ). However, with four daily deferiprone doses the mean LPI level did not exceed the 0.6 mm level during the day (until midnight), whereas with three doses it significantly exceeded that level by evening (18 24 hours). Whether spreading out the total daily dose of deferiprone has a similar effect on independent parameters of body iron status/burden remains to be determined. Thalasemia major L1 n=9, L1: x4 daily n=10,l1: x3 daily 2.0 LPI µm time of sampling/treatment (hr) Figure 3. Mean LPI levels in thalassemia major patients treated with the same total daily dose of deferiprone divided differently. The following depicts the mean LPIGSEM values obtained from groups of nine or ten thalassemia major (same) patients treated with deferiprone orally (arrows) in three versus four daily doses. The height of a given area at a particular time depicts the level of the parameter at the indicated hour of sampling (every other hour from 8 a.m. until midnight). Time of sampling/treatment represents the time of day (in hours) at which either blood samples were withdrawn or drug was delivered. LPI exceeded the 0.6 mm threshold: (a) 8 (or 32), 18, 20 and 24 hours for the three-dose group, and (b) 8 (or 32) for the four-dose group. The white mesh represents the precision limit of the assay or background level found also in sera from normal individuals. Modified from Zanninelli et al (2004, Proceedings of the European Iron Club meeting, Rennes 2004) with permission.
9 LPI-labile plasma iron in iron overload 285 SUMMARY LPI values obtained following an extended drug washout period (basal LPI levels) provide a means for evaluating the efficacy of treatment in maintaining the individual at low levels of exposure to labile plasma iron. LPI values vary among iron-overloaded patients in relation to the regimen of chelation and time of blood withdrawal. Although the basal LPI levels decline relatively faster than other iron-related parameters, they correlate linearly with serum ferritin levels as well as with red-cell-membrane-associated iron. The combined deferiproneplus-dfo treatment yield the lowest basal LPI values and serum ferritin values, as compared to those obtained with DFO or deferiprone alone. LPI levels were considered highly significant in terms of iron overload if they exceeded by 100% the assay meangsd background/noise level of 0.4G0.2 mm, i.e. if LPI levels were O0.6 mm. Unlike combined deferiprone-plus-dfo-treated patients, who showed no significant LPI during the entire day, those treated with either DFO alone or deferiprone alone showed a non-uniform behavior with respect to daily LPI levels. Some patients subjected to monotherapy were found not to have significant basal LPI levels at any time during the day, whereas others had only after prolonged washout times, and some during most hours of the day. The individual daily basal values of LPI or daily profiles of LPI can be used for optimizing chelation treatment (dosage regimen: number of doses per day, single or combined therapy, etc.) so as to attain a full-day coverage of LPI-preventing activity. In the deferiprone-treated group a significant improvement in diminishing daily LPI was achieved just by spreading the daily treatment from three to four deferiprone doses. However, the clinical outcome of spreading the deferiprone treatment remains to be further assessed. Practice points for clinical trials or preliminary assessment of deferiprone and/or DFO regimens of treatment, the incorporation of LPI assays should be based on a selected schedule of blood sample withdrawals (followed by serum preparation, separation and deep-freeze storage; ca. 0.5 ml total serum sample) the number of blood samples to be taken might depend on the availability of patients. All samples should be taken before drug intake (orally or by infusion) and if possible at different washout periods: (a) at the onset and end of treatment it might be useful to obtain a complete daily profile: 2 10 samples during a 24-hour period (7 8 a.m. to midnight, 2 or 12 hours apart and 24 hours later); if only one or two daily samples are available, then one should consider sampling after a drug washout period of at least 4 hours for deferiprone or for DFO, preferably on two consecutive days; (b) during treatment, one blood sample (basal LPI) every 2 months or as often as required or available in the morning before deferiprone intake and before DFO infusion analogous schedules can be designed for assessing ICL670 as well as other novel iron chelators
10 286 Z. I. Cabantchik et al. Research agenda LPI is being evaluated as a surrogate marker for assessing the efficacy of chelation regimens in diminishing iron loads in general, and with special attention to removal of cardiac iron with view to improving affected cardiac functions ACKNOWLEDGEMENTS This work was supported in part by The European Community 5th Framework QLRT (nutrient iron toxicity) and by Apopharma Inc, Ont., Canada. REFERENCES 1. Weatherall DJ. Pathophysiology of thalassaemia. Baillieres Clin Haematol 1998; 11: Kushner JP, Porter JP & Olivieri NF. Secondary iron overload. Hematology (Am Soc Hematol Educ Program) 2001; Merson L & Olivieri N. Orally active iron chelators. Blood Rev 2002; 16: Liu ZD & Hider RC. Design of clinically useful iron(iii)-selective chelators. Med Res Rev 2002; 22: Brittenham GM, Sheth S, Allen CJ & Farrell DE. Noninvasive methods for quantitative assessment of transfusional iron overload in sickle cell disease. Semin Hematol 2001; 38(supplement 1): Hoffbrand AV, Cohen A & Hershko C. Role of deferiprone in chelation therapy for transfusional iron overload. Blood 2003; 102: Fischer R & Engelhardt R. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility. Lancet 2003; 361: *8. Fischer R, Longo F, Nielsen P et al. Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with beta-thalassaemia major: application of SQUID biomagnetic liver susceptometry. Br J Haematol 2003; 121: *9. Piga A, Gaglioti C, Gogliacco E & Tricta F. Comparative effects of defriprone and deferioxamine on survival and cardiac disease in thalasssemia major: a -retrospective study. Hematologia 2003; 88: *10. Galia M, Midiri M, Bartolotta Vet al. Multicenter trial group of the society for the study of thalassemia and haemoglobinopathies. Potential myocardial iron content evaluation by magnetic resonance imaging in thalassemia major patients treated with Deferoxamine or Deferiprone during a randomized multicenter prospective clinical study. Hemoglobin. 2003; 27: *11. Jensen PD, Jensen FT, Christensen T et al. Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool. Blood 2003; 101: Ooi GC, Khong PL, Chan GCF et al. Magnetic resonance screening of iron status in transfusiondependent b-thalassaemia patients. Br J Haematol 2004; 124: Papanikolaou N, Ghiatas A, Kattamis A et al. Non-invasive myocardial iron assessment in thalassaemic patients: T2 relaxometry and magnetization transfer ratio measurements. Acta Radiol 2000; 41: Westwood M, Anderson LJ & Pennell DJ. Treatment of cardiac iron overload in thalassemia major. Haematologica 2003; 88: *15. Wood JC, Tyszka JM, Carson S et al. Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease. Blood 2004; 103: Mancuso L, Panzarella G, Bartolotta TVet al. Cardiac complications in thalassemia: noninvasive detection methods and new directions in the clinical management. Expert Rev Cardiovasc Ther 2003; 1:
11 LPI-labile plasma iron in iron overload Hershko C, Graham G, Bates GW & Rachmilewitz EA. Non-specific serum iron in thalassaemia: an abnormal serum iron fraction of potential toxicity. Br J Haematol 1978; 40: *18. Breuer W, Hershko C & Cabantchik ZI. The importance of non-transferrin bound iron in disorders of iron metabolism. Transfus Sci 2000; 23: Gosriwatana I, Loreal O, Lu S et al. Quantification of non-transferrin-bound iron in the presence of unsaturated transferrin. Anal Biochem 1999; 273: Porter JB, Abeysinghe RD, Marshall L et al. Kinetics of removal and reappearance of non-transferrinbound plasma iron with deferoxamine therapy. Blood 1996; 88: Breuer W & Cabantchik ZI. A fluorescence-based one-step assay for serum non-transferrin-bound iron. Anal Biochem 2001; 299: *22. Esposito BP, Breuer W, Sirankapracha P et al. Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood 2003; 102: *23. Pootrakul P, Breuer W, Sametband M et al. Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron overloaded beta-thalassaemia/hbe patients treated with an oral chelator. Blood 2004; 104: Giardina PJ & Grady RW. Chelation therapy in beta-thalassemia: an optimistic update. Semin Hematol 2001; 38: Modell B, Khan M & Darlison M. Survival in betathalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet 2000; 355: Olivieri NF, Nathan DG, MacMillan JH et al. Survival in medically treated patients with homozygous betathalassemia. N Engl J Med 1994; 331: *27. Hershko C, Cappellini MD, Galanello R et al. Purging iron from the heart. Br J Haematol 2004; 125: Anderson LJ, Holden S, Davis B et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001; 22: Anderson LJ, Wonke B, Prescott E et al. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet 2002; 360: Gunshin H, Mackenzie B, Berger UV et al. Cloning and characterization of a proton-coupled mammalian metal ion transporter. Nature 1997; 388: *31. Oudit GY, Sun H, Trivieri MG et al. L-type Ca2C channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy. Nat Med 2003; 9: Davis BA & Porter JB. Results of long term iron chelation treatment with deferoxamine. Adv Exp Med Biol 2002; 509: Le Lan C, Cohen T, Ropert M et al. Labile plasma iron in C282Y/C282Y hemochromatosis: a reality of potential pathophysiological and clinical importance. Le Lan C, Cohen Hepatol 2003; 38(No. 4 supplement 1): 661A. 34. Breuer W, Ermers MJ, Pootrakul P et al. Desferrioxamine-chelatable iron, a component of serum nontransferrin-bound iron, used for assessing chelation therapy. Blood 2001; 97: Sulieman M, Asleh R, Cabantchik ZI et al. Serum chelatable redox-active iron is an independent predictor of mortality after myocardial infarction in individuals with diabetes mellitus. Diabetes Care 2004; 27: Winder A, Cabantchik ZI, Merkel D & Rachmilewitz EA. Possible implications of measurable quantities of non transferrin bound iron (NTBI) in Myelodysplastic Syndrome. Blood 2003; 102(11): 916a.
Labile Plasma Iron: The Need and the Answer
Labile Plasma Iron: The Need and the Answer Z. Ioav Cabantchik and William Breuer Department of Biological Chemistry, The Hebrew University of Jerusalem, 91904 Jerusalem, Israel Chronic diseases of iron
More informationFerriScan provides an accurate assessment of body iron stores
FerriScan provides an accurate assessment of body iron stores A clinician s guide to managing transfusional iron overload with FerriScan Transfusional iron overload Patients receiving multiple blood transfusions
More informationDaily labile plasma iron as an indicator of chelator activity in Thalassaemia major patients
research paper Daily labile plasma iron as an indicator of chelator activity in Thalassaemia major patients Giuliana Zanninelli, 1 William Breuer and Zvi I. Cabantchik 1 Unita Day Hospital Talassemici,
More informationSurvival and Disease Complication of Thalassemia Major: Experience of 14 Years at King Abdulaziz University Hospital, Jeddah, KSA
JKAU: Med. Sci., Vol. 17 No. 1, pp: 19-28 (2010 A.D. / 1431 A.H.) DOI: 10.4197/Med. 17-1.3 Survival and Disease Complication of Thalassemia Major: Experience of 14 Years at King Abdulaziz University Hospital,
More informationReal-World Use of Iron Chelators
STRATEGIES FOR OPTIMAL MANAGEMENT OF THALASSEMIA NOW AND IN THE FUTURE Real-World Use of Iron Chelators Janet L. Kwiatkowski 1 1 Children s Hospital of Philadelphia and University of Pennsylvania School
More informationEvaluation of Cardiac Iron Load by Cardiac Magnetic Resonance in Thalassemia
R E S E A R C H P A P E R Evaluation of Cardiac Iron Load by Cardiac Magnetic Resonance in Thalassemia RASHID MERCHANT, ADITI JOSHI, JAVED AHMED, *PRADEEP KRISHNAN AND *BHAVIN JANKHARIA From the Department
More informationBaseline investigations prior to starting chelation therapy include: Serum ferritin, transferrin saturation, creatinine and liver enzymes.
14. IRON OVERLOAD Principles To prevent transfusional iron overload in SCD. To diagnose and monitor transfusional iron overload. To initiate the appropriate iron chelation therapy at the appropriate time.
More informationImpact of Iron Assessment by MRI
STRATEGIES FOR OPTIMAL MANAGEMENT IN THALASSEMIA NOW AND IN THE FUTURE Impact of Iron Assessment by MRI John C. Wood 1 1 Children s Hospital Los Angeles, Los Angeles, CA The use of magnetic resonance imaging
More informationNon-transferrin-bound iron and its labile (redox active) plasma
ARTICLE Iron Metabolism & Its Disorders EUROPEAN HEMATOLOGY ASSOCIATION Haematologica 2016 Volume 101(1):38-45 Ferrata Storti Foundation Second international round robin for the quantification of serum
More informationAustralian Guidelines for the assessment of iron overload and iron. chelation in transfusion-dependent thalassaemia major, sickle cell
1 Received date: 10/15/2010 Accepted date: 04/05/2011 Australian Guidelines for the assessment of iron overload and iron chelation in transfusion-dependent thalassaemia major, sickle cell disease and other
More informationIron Overload in Sickle Cell Disease Review of Cause and Treatment
Iron Overload in Sickle Cell Disease Review of Cause and Treatment Susan M. Carson RN, MSN, CPNP Nurse Practitioner III Hematology Program Children s Hospital Los Angeles Objectives Describe the effect
More informationDeferasirox in Indian children with thalassemia major: 3 years experience
[Downloaded free from http://www.ijmpo.org on Friday, June 14, 2013, IP: 109.112.89.28] Click here to download free Android application for this journa ORIGINAL ARTICLE Deferasirox in Indian children with
More informationIron Overload Disorders and Iron Chelation Therapy
Iron Overload Disorders and Iron Chelation Therapy T. Lodewyck BHS seminar November 2014 Outline Iron overload (IO) disorders Mechanisms and pathophysiology of IO Clinical impact of IO Assessment of IO
More informationNuovi Approcci alla Ferrochelazione
Il Deficit di PKD 1 patient day Nuovi Approcci alla rrochelazione M. Domenica Cappellini Fondazione Ca Granda Policlinico Università di Milano Milano May 16 2015 Genetic and acquired iron overload Genetic
More informationThe iron chelator deferoxamine has been available
Transfusion Iron Overload research paper Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis ANTONIO PIGA, CARMEN
More informationFAQ on FerriScan asked by clinical communities
FAQ on FerriScan asked by clinical communities We measure cardiac T2* of our patients, why is it important to measure liver iron concentration (LIC) as well? Measuring cardiac T2* is important as a significant
More informationSetting The setting was secondary care. The economic study was carried out in the USA.
Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients: US healthcare system perspective Delea T E, Sofrygin
More informationDaily alternating deferasirox and deferiprone therapy for hard-to-chelate β-thalassemia major patients
Daily alternating deferasirox and deferiprone therapy for hard-to-chelate β-thalassemia major patients Manuela Balocco, Paola Carrara, Valeria Pinto, Gian Luca Forni To cite this version: Manuela Balocco,
More informationDrug Review. Deferasirox: The New Oral Iron Chelator
Drug Review Deferasirox: The New Oral Iron Chelator A.P. Dubey S. Sudha Ankit Parakh Deferasirox is a new tridentate oral iron chelator developed by computer remodeling recently approved by FDA for children
More informationMyocardial iron load measured by cardiac magnetic resonance imaging to evaluate cardiac systolic function in thalassemia.
Myocardial iron load measured by cardiac magnetic resonance imaging to evaluate cardiac systolic function in thalassemia Masoumeh Kahnooji (1), Hamid Reza Rashidinejad (2), Mohammad Shahram Yazdanpanah
More informationA clinical audit of thalassaemia management at the Lady Ridgeway Hospital for Children, Colombo
Original Articles A clinical audit of thalassaemia management at the Lady Ridgeway Hospital for Children, Colombo P S Samarakoon 1, A P Wijesuriya 2 Sri Lanka Journal of Child Health, 2011; 40: 48-53 (Key
More informationISSN Asian Journal of Medical and Pharmaceutical Researches Asian J. Med. Pharm. Res. 3(3): 93-97, 2013
\\\\ 2013, Scienceline Publication www.science-line.com ISSN 2322-4789 Asian Journal of Medical and Pharmaceutical Researches Asian J. Med. Pharm. Res. 3(3): 93-97, 2013 AJMPR Comparison of Therapeutic
More informationDEFERASIROX IN THE TREATMENT OF TRANSFUSIONAL IRON OVERLOAD IN THALASSAEMIA MAJOR AND OTHER ANAEMIAS (April 2011)
DEFERASIROX IN THE TREATMENT OF TRANSFUSIONAL IRON OVERLOAD IN THALASSAEMIA MAJOR AND OTHER ANAEMIAS (April 2011) Version: Ratified by (name of Committee): Date ratified: Date issued: Expiry date: (Document
More informationClass Update: Iron Chelators. Month/Year of Review: June 2015 Date of Last Review: June 2012
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationClinical Guidelines on the Use of Iron Chelation in Children Receiving Regular Blood Transfusions
Clinical Guidelines on the Use of Iron Chelation in Children Receiving Regular Blood Transfusions Version: 1 Date: 4 th May 2010 Authors: Responsible committee or Director: Review date: Target audience:
More informationA group of inherited disorders characterized by reduced or absent amounts of hemoglobin, the oxygencarrying protein inside the red blood cells.
Thalassemia A group of inherited disorders characterized by reduced or absent amounts of hemoglobin, the oxygencarrying protein inside the red blood cells. Types of Thallasemia 1) Thalassemia trait 2)
More informationLa Terapia della Talassemia
S.I.E. Corso nazionale di aggiornamento in ematologia clinica La Terapia della Talassemia Renzo Galanello 15/06/2007 1 Clinica Pediatrica 2-Ospedale Regionale Microcitemie.ASL8 Clinical characteristics
More informationΧριστίνα Χρυσοχόου Α Καρδιολογική Κλινική Πανεπιστηίου Αθηνών
Ιωάννης Ανδρέου Χριστίνα Χρυσοχόου Α Καρδιολογική Κλινική Πανεπιστηίου Αθηνών Ιπποκράτειο Γ.Ν.Α Splenectomy at the age of 7yrs Episodes of persistent atrial fibrillation Hypothyroidism Osteoporosis Noncompliant
More informationEffective Iron Chelation Practice for Patients With β-thalassemia Major
Downloaded on 12 02 2018. Single-user license only. Copyright 2018 by the Oncology Nursing Society. For permission to post online, reprint, adapt, or reuse, please email pubpermissions@ons.org Article
More informationNontransferrin-bound iron and labile plasma iron in relation to iron toxicity NTBI unraveling the confusion LPI
Nontransferrin-bound iron and labile plasma iron in relation to iron toxicity NTBI unraveling the confusion LPI Z. Ioav Cabantchik Institute of Life Sciences Hebrew University of Jerusalem Disclosure of
More informationBETA thalassemia is one of the most
Effect of Deferiprone on Urinary Zinc Excretion in Multiply Transfused Children with Thalassemia Major Sandip Bartakke, S.B. Bavdekar, Pratima Kondurkar, Mamta N. Muranjan, Mamata V. Manglani* and Ratna
More informationToward optimizing the use of deferasirox: potential benefits of combined use with deferoxamine
Thalassemia Syndromes Toward optimizing the use of deferasirox: potential benefits of combined use with deferoxamine ARTICLES Robert W. Grady¹, Renzo Galanello², Rachel E. Randolph¹, Dorothy A. Kleinert¹,
More informationStudy on Safety and Efficacy of Deferasirox in the treatment of Thalassemia in a South Indian Tertiary Care Hospital
Research Article Study on Safety and Efficacy of Deferasirox in the treatment of Thalassemia in a South Indian Tertiary Care Hospital Siva Shankar Reddy Y *1, Umesh Kamrthi 2 and Balasubramanian Kumar
More informationEffects of monotherapy and combined therapy on LPI
Effects of monotherapy and combined therapy on LPI 14 12 DFO 40 mg/kg/day 14 12 Deferiprone 75 mg/kg/day 14 12 Deferiprone 75 mg/kg/day DFO 40 mg/kg/day DFO 40 mg/kg/day LPI (μm) 10 8 6 LPI (μm) 10 8 6
More informationThe concentration and total amounts of iron in
IRON OVERLOAD Non-invasive assessment of tissue iron overload Roland Fischer 1,2 and Paul R. Harmatz 2 1 University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 2 Children s Hospital & Research
More informationComparison between different software programs and techniques for liver iron concentration assessment with MRI in thalassemic patients
Comparison between different software programs and techniques for liver iron concentration assessment with MRI in thalassemic patients Poster No.: C-1580 Congress: ECR 2015 Type: Scientific Exhibit Authors:
More informationIron overload in transfusion-dependent survivors of hemoglobin Bart s hydrops fetalis
Published Ahead of Print on January 25, 2018, as doi:10.3324/haematol.2017.178368. Copyright 2018 Ferrata Storti Foundation. Iron overload in transfusion-dependent survivors of hemoglobin Bart s hydrops
More informationThe thalassaemias are common genetic
Hellenic J Cardiol 2011; 52: 385-390 Editorial Evaluation of Myocardial Iron Overload Using Cardiovascular Magnetic Resonance Imaging Sophie Mavrogeni 1, Alessia Pepe 2, Massimo Lombardi 2 1 Onassis Cardiac
More informationCorporate Medical Policy Chelation Therapy
Corporate Medical Policy Chelation Therapy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: chelation_therapy 12/1995 2/2015 2/2016 2/2015 Description of Procedure or Service Chelation
More informationDetection of Hepatotoxicity by Non-Transferrin Bound Iron in Beta Thalassemia Major
Original Article Detection of Hepatotoxicity by Non-Transferrin Bound Iron in Beta Thalassemia Major Asma Naseer Cheema, Dilshad Ahmed Khan Department of Pathology Army Medical College, National University
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Exjade, Jadenu) Reference Number: CP.PHAR.145 Effective Date: 11.01.15 Last Review Date: 08.18 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end
More informationOverview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload
Int J Hematol (2008) 88:24 29 DOI 10.1007/s12185-008-0118-z PROGRESS IN HEMATOLOGY Transfusional iron overload and iron chelation therapy Overview of guidelines on iron chelation therapy in patients with
More informationIron chelation monotherapy in transfusion-dependent beta-thalassemia major patients: a comparative study of deferasirox and deferoxamine
Electronic Physician (ISSN: 2008-5842) http://www.ephysician.ir May 2016, Volume: 8, Issue: 5, Pages: 2425-2431, DOI: http://dx.doi.org/10.19082/2425 Iron chelation monotherapy in transfusion-dependent
More informationCorporate Medical Policy
Corporate Medical Policy Chelation Therapy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: chelation_therapy 12/1995 2/2017 2/2018 2/2017 Description of Procedure or Service Chelation
More informationComparing the efficacy of Dexeroyx (Osveral) and Deferoxamine (Desferal) in reducing serum ferritin level in patients with thalassemia major
Comparing the efficacy of Dexeroyx (Osveral) and Deferoxamine (Desferal) in reducing serum ferritin level in patients with thalassemia major Ali Hajigholami (1) Hourieh Ansari (2) Saeid Honarmand (3) (1)
More informationHEPATIC IRON CONCENTRATION AND TOTAL BODY IRON STORES IN THALASSEMIA MAJOR HEPATIC IRON CONCENTRATION AND TOTAL BODY IRON STORES IN THALASSEMIA MAJOR
HEPATIC IRON CONCENTRATION AND TOTAL BODY IRON STORES IN THALASSEMIA MAJOR EMANUELE ANGELUCCI, M.D., GARY M. BRITTENHAM, M.D., CHRISTINE E. MCLAREN, PH.D., MARTA RIPALTI, PH.D., DONATELLA BARONCIANI, M.D.,
More informationBrazilian Thalassemia Association protocol for iron chelation therapy in patients under regular transfusion
Special Article Brazilian Thalassemia Association protocol for iron chelation therapy in patients under regular transfusion Monica Pinheiro de Almeida Veríssimo 1 Sandra Regina Loggetto 2 Antonio Fabron
More informationConsensus view on choice or iron chelation therapy in transfusional iron overload for inherited anaemias
Consensus view on choice or iron chelation therapy in transfusional iron overload for inherited anaemias The goal of iron chelation therapy in multiply transfused patients is to prevent morbidity and early
More informationThalassaemia & the heart
Thalassaemia & the heart Dr. Malcolm Walker Consultant Cardiologist University College & the National Heart Hospital London Clinical Director Hatter Cardiovascular Institute UCLH JMW 2010 3 rd Pan American
More informationMyocardial Iron Loading in Patients with Thalassemia Major on Deferoxamine Chelation
Journal of Cardiovascular Magnetic Resonance (2006) 8, 543 547 Copyright c 2006 Taylor & Francis Group, LLC ISSN: 1097-6647 print / 1532-429X online DOI: 10.1080/10976640600698155 CARDIOMYOPATHY Myocardial
More informationHow Early Can Myocardial Iron Overload Occur in Beta Thalassemia Major?
How Early Can Myocardial Iron Overload Occur in Beta Thalassemia Major? Gaohui Yang 1., Rongrong Liu 1., Peng Peng 2, Liling Long 2, Xinhua Zhang 3, Weijia Yang 4, Shaohong Tan 5, Hongfei Pan 6, Xingjiang
More informationPrevalence of fractures among Thais with thalassaemia syndromes
817 Original Article Prevalence of fractures among Thais with thalassaemia syndromes Sutipornpalangkul W, Janechetsadatham Y, Siritanaratkul N, Harnroongroj T Department of Orthopaedic Surgery, Faculty
More informationRisks and Benefits of Blood Transfusions. Objectives. Red Cells (Erythrocytes) Understand the following:
Risks and Benefits of Blood Transfusions Patient and Family Conference Aplastic Anemia & MDS International Foundation July 10-12 th, 2009 Indianapolis, Indiana Susan M. Carson RN, MSN, CPNP Childrens Hospital
More informationCorporate Medical Policy
Corporate Medical Policy Chelation Therapy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: chelation_therapy 12/1995 2/2018 2/2019 2/2018 Description of Procedure or Service Chelation
More informationTherapie mit Eisenchelatoren bei chronischen Anämien
1 Therapie mit Eisenchelatoren bei chronischen Anämien 1) Tanno T, et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nature Medicine 2007;13:1096-101.
More informationClinical Medicine: Therapeutics. Management of Transfusional Chronic Iron Overload: Focus on Deferasirox
Clinical Medicine: Therapeutics R e v i e w Open Access Full open access to this and thousands of other papers at http://www.la-press.com. Management of Transfusional Chronic Iron Overload: Focus on Deferasirox
More information1st International Working Group on Thalassemia:
1st International Working Group on Thalassemia: Effectiveness and safety of 10 different regimens for controlling iron overloading in Thalassemia Major CAMPUS OF HEMATOLOGY "Franco e Piera Cutino" A.O.R.
More informationCardiac T2* Magnetic Resonance for Prediction of Cardiac Complications in Thalassemia Major
Cardiac T2* Magnetic Resonance for Prediction of Cardiac Complications in Thalassemia Major CIRCULATIONAHA/2009/874487 Kirk P; MB MRCP 1 Roughton M; MSc 2 Porter JB; MD FRCP 3 Walker JM; MD FRCP 4 Tanner
More informationIron Chelator Drug Class Monograph
Iron Chelator Drug Class Monograph Line of Business: Medi-Cal Effective Date: May 17, 2017 Revision Date: May 17, 2017 This policy has been developed through review of medical literature, consideration
More informationThe Nucleated Red Blood Cell (NRBC) Count in Thalassaemia Syndromes Paolo Danise and Giovanni Amendola
7. The Nucleated Red The Nucleated Red Blood Cell (NRBC) Count in Thalassaemia Syndromes Paolo Danise and Giovanni Amendola Introduction The purpose of this study was to evaluate the performance of the
More informationJMSCR Vol 06 Issue 08 Page August 2018
www.jmscr.igmpublication.org Impact Factor (SJIF): 6.379 Index Copernicus Value: 71.58 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v6i8.08 A study on safety and efficacy
More informationHow far one should go with iron chelation in thalassemia? Is iron deficiency indicated?
How far one should go with iron chelation in thalassemia? Is iron deficiency indicated? DR. KALLISTHENI FARMAKI THALASSAEMIA UNIT GENERAL HOSPITAL OF CORINTH, GREECE VASILI BERDOUKAS PEDIATRIC HEMATOLOGIST
More informationReview Article Iron Overload in Sickle Cell Disease
Advances in Hematology Volume 2010, Article ID 272940, 9 pages doi:10.1155/2010/272940 Review Article Iron Overload in Sickle Cell Disease Radha Raghupathy, 1 Deepa Manwani, 2 and Jane A. Little 1 1 Department
More informationCORRELATION BETWEEN PROTHROMBIN TIME AND SERUM FERRITIN LEVEL IN THALASSAEMIA PATIENTS
CORRELATION BETWEEN PROTHROMBIN TIME AND SERUM FERRITIN LEVEL IN THALASSAEMIA PATIENTS NASIMA SULTANA 1, SALMA SADIYA 2 Associate professor & Head, Dept. of Biochemistry, Dhaka Medical College, Dhaka 1,
More informationOriginal Article Deferiprone challenge test for monitoring iron overload in hepatitis positive thalassemic major patients
Int J Clin Exp Med 2010;3(2):122-128 www.ijcem.com /IJCEM1001006 Original Article Deferiprone challenge test for monitoring iron overload in hepatitis positive thalassemic major patients Dilshad A. Khan
More informationRepeated IV doses of iron provides effective supplemental treatment of restless legs syndrome
Sleep Medicine 6 (2005) 301 305 www.elsevier.com/locate/sleep Original article Repeated IV doses of iron provides effective supplemental treatment of restless legs syndrome Christopher J. Earley*, Debbie
More informationCorporate Medical Policy Genetic Testing for Hereditary Hemochromatosis
Corporate Medical Policy Genetic Testing for Hereditary Hemochromatosis File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_hemochromatosis 5/2012 3/2018 3/2019 3/2018
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationIN patients with thalassemia major, a regular program
918 THE NEW ENGLAND JOURNAL OF MEDICINE April 6, 1995 IRON-CHELATION THERAPY WITH ORAL DEFERIPRONE IN PATIENTS WITH THALASSEMIA MAJOR NANCY F. OLIVIERI, M.D., GARY M. BRITTENHAM, M.D., DOREEN MATSUI, M.D.,
More informationBenign Disorders. Loree Larratt, MD University of Alberta
Benign Disorders Loree Larratt, MD University of Alberta Disclosures Ad boards, honorarium: Alexion, Novartis, Lundbeck, Roche Agenda Iron Overload CARE Iron Chelation Needs Assessment Program Update Myeloproliferative
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationIntroduction ORIGINAL ARTICLE
ORIGINAL ARTICLE Downloaded from ijbc.ir at 8:25 +0430 on Saturday September 1st 2018 IJBC 2010;1: 1-5 A Glance at the Cost of Chelation Therapy with Desferal and Exjade in Iran Hadipour Dehshsal M 1 *,
More informationKELFER Deferiprone. COMPOSITION KELFER-250 Capsules Each capsule contains Deferiprone 250 mg
KELFER Deferiprone COMPOSITION KELFER-250 Capsules Each capsule contains Deferiprone 250 mg KELFER-500 Capsules Each capsule contains Deferiprone 500 mg DOSAGE FORM Capsules PHARMACOLOGY Pharmacodynamics
More informationKELFER Capsules (Deferiprone)
Published on: 22 Sep 2014 KELFER Capsules (Deferiprone) Composition KELFER-250 Capsules Each capsule contains Deferiprone 250 mg KELFER-500 Capsules Each capsule contains Deferiprone 500 mg Dosage Form
More informationMEDICAL POLICY SUBJECT: CHELATION THERAPY. POLICY NUMBER: CATEGORY: Technology Assessment
MEDICAL POLICY SUBJECT: CHELATION THERAPY PAGE: 1 OF: 5 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product, including an
More informationOriginal Research JOURNAL OF MAGNETIC RESONANCE IMAGING 29: (2009)
JOURNAL OF MAGNETIC RESONANCE IMAGING 29:853 859 (2009) Original Research Assessment of Iron Distribution Between Liver, Spleen, Pancreas, Bone Marrow, and Myocardium by Means of R2 Relaxometry With MRI
More informationImaging. Cardiac T2* Magnetic Resonance for Prediction of Cardiac Complications in Thalassemia Major
Imaging Cardiac T2* Magnetic Resonance for Prediction of Cardiac Complications in Thalassemia Major P. Kirk, MB, MRCP; M. Roughton, MSc; J.B. Porter, MD, FRCP; J.M. Walker, MD, FRCP; M.A. Tanner, MB, MRCP;
More informationICH Topic S1C(R2) Dose Selection for Carcinogenicity Studies of Pharmaceuticals. Step 5
European Medicines Agency October 2008 EMEA/CHMP/ICH/383/1995 ICH Topic S1C(R2) Dose Selection for Carcinogenicity Studies of Pharmaceuticals Step 5 NOTE FOR GUIDANCE ON DOSE SELECTION FOR CARCINOGENICITY
More informationRegular teaching provided in ED, Paediatric Specialist Trainees Regional Training days and nursing training programmes.
Iron chelation in Children with Haemoglobinopathy Trust Ref: C19/2016 1. Introduction The goal of iron chelation therapy in multiply transfused patients is to prevent morbidity and early mortality from
More informationLabile plasma iron in iron overload: redox activity and susceptibility to chelation
RED CELLS Labile plasma iron in iron overload: redox activity and susceptibility to chelation Breno P. Esposito, William Breuer, Pornpan Sirankapracha, Pensri Pootrakul, Chaim Hershko, and Z. Ioav Cabantchik
More informationEvaluation of Cardiac Complications in Patients with Thalassemia Major Using Serum Ferritin Levels
Original Article Print ISSN: 2321-6379 Online ISSN: 2321-595X DOI: 10.17354/ijssJuneI/2017/016 Evaluation of Cardiac Complications in Patients with Thalassemia Major Using Serum Ferritin Levels Farideh
More informationTHALASSEMIA AND COMPREHENSIVE CARE
1 THALASSEMIA AND COMPREHENSIVE CARE Melanie Kirby MBBS, FRCP (C), Hospital for Sick Children, Toronto Associate Professor of Paediatrics, University of Toronto. Objectives 2 By the end of this presentation,
More informationMD (Res) Thesis University Of London. Sunil Viswanathan Nair
The Role Of Brain Natriuretic Peptide And Tissue Doppler Echocardiography in the Management of Transfusion Dependent Thalassaemia Patients MD (Res) Thesis University Of London Sunil Viswanathan Nair 1
More informationIron Chelation therapy in Thalassaemia Patients journey
Iron Chelation therapy in Thalassaemia Patients journey George Constantinou 11 th Annual sickle cell disease and Thalassaemia conference (ASCAT)2017 George Constantinou ASCAT 2017 1 Thalassaemia Major
More informationProf Sanath P Lamabadusuriya
Prof Sanath P Lamabadusuriya What is Thalassaemia? It is the commonest inherited variety of anaemia It is the commonest haemoglobinopathy in Sri Lanka Of all the different types, Beta-Thalassaemia major
More informationHemosiderin. Livia Vida 2018
Hemosiderin Livia Vida 2018 Questions Histochemical caracteristics of the different pigments. Exogenous pigments. Hemoglobinogenic pigments. Causes and forms of jaundice. Hemoglobinogenic pigments. Pathological
More informationBeta-thalassemia major (TM) affects births per. Imaging
Imaging A Randomized, Placebo-Controlled, Double-Blind Trial of the Effect of Combined Therapy With Deferoxamine and Deferiprone on Myocardial Iron in Thalassemia Major Using Cardiovascular Magnetic Resonance
More informationPOLICIES AND PROCEDURE MANUAL
POLICIES AND PROCEDURE MANUAL Policy: MP081 Section: Medical Benefit Policy Subject: Chelation Therapy I. Policy: Chelation Therapy II. Purpose/Objective: To provide a policy of coverage regarding Chelation
More informationPart I. Pathophysiology and management of Thalassemia Intermedia. M. Domenica Cappellini Fondazione IRCCS Policlinico University of Milan
Pathophysiology and management of Thalassemia Intermedia M. Domenica Cappellini Fondazione IRCCS Policlinico University of Milan 4th European Symposium on Rare Anaemias 3rd Bulgarian Symposium on Thalassaemia
More informationABNORMALITIES IN LUNG FUNCTION AMONG MULTIPLY- TRANSFUSED THALASSEMIA PATIENTS: RESULTS FROM A THALASSEMIA CENTER IN MALAYSIA
ABNORMALITIES IN LUNG FUNCTION AMONG MULTIPLY- TRANSFUSED THALASSEMIA PATIENTS: RESULTS FROM A THALASSEMIA CENTER IN MALAYSIA R Jamal 1, J Baizura 1, A Hamidah 1, N Idris 2, AH Jeffrey 3 and H Roslan 3
More informationCombined Oral and Parenteral Iron Chelation in Beta Thalassaemia Maior
Combined Oral and Parenteral Iron Chelation in Beta Thalassaemia Maior K Balveer, MRCP*, K Pyar, FRCP*, B Wonke, FRCP**, *Departtnent of Paediatrics, Penang Hospital, Residency Road, 10450 Penang, **Department
More informationThe safe and accurate measurement of liver iron concentration. Information for Patients
The safe and accurate measurement of liver iron concentration Information for Patients What you need to know What is iron overload? Iron overload is the accumulation of too much iron in the body. People
More informationClinical Study Hepatic Iron Quantification on 3 Tesla (3 T) Magnetic Resonance (MR): Technical Challenges and Solutions
Radiology Research and Practice Volume 2013, Article ID 628150, 7 pages http://dx.doi.org/10.1155/2013/628150 Clinical Study Hepatic Iron Quantification on 3 Tesla (3 T) Magnetic Resonance (MR): Technical
More informationPreface: Thalassemia Bernard G. Forget
Thalassemia Preface: Thalassemia Bernard G. Forget xiii Thalassemia: An Overview of 50 Years of Clinical Research 1005 Vijay G. Sankaran and David G. Nathan The thalassemias are attributable to the defective
More informationAssessment of Iron Overload in Homozygous and Heterozygous Beta Thalassemic Children below 5 Years of Age
ISSN 2231-4261 ORIGINAL ARTICLE Assessment of Iron Overload in Homozygous and Heterozygous Beta Thalassemic Children below 5 Years of Age 1* 2 Dhiraj J. Trivedi, Aparna Sagare 1 Department of Biochemistry,
More informationStandards of Care in Thalassemia. What is Thalassemia?
Standards of Care in Thalassemia Thalassemia Support group Thomas D Coates, MD Childrens Hospital Los Angeles What is Thalassemia? Thalassemia is an inherited disorder due to a DNA mutation that causes
More informationIntracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells
RED CELLS Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells Hava Glickstein, Rinat Ben El, Maya Shvartsman, and Z. Ioav Cabantchik
More informationINTRAVENOUS CHELATION THERAPY DURING TRANSPLANTATION FOR THALASSEMIA
original paper Haematologica 1995; 80:300-304 INTRAVENOUS CHELATION THERAPY DURING TRANSPLANTATION FOR THALASSEMIA Djavid Gaziev, Claudio Giardini, Emanuele Angelucci, Paola Polchi, Mariella Galimberti,
More information